Renovaro Inc. 2Q5.F Stock
Renovaro Inc. Price Chart
Renovaro Inc. 2Q5.F Financial and Trading Overview
| Renovaro Inc. stock price | 0.81 EUR |
| Previous Close | 0.52 EUR |
| Open | 0.53 EUR |
| Bid | 0.53 EUR x N/A |
| Ask | 0.77 EUR x N/A |
| Day's Range | 0.53 - 0.53 EUR |
| 52 Week Range | 0.53 - 3.29 EUR |
| Volume | 3K EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 31.99M EUR |
| Beta (5Y Monthly) | 1.098591 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.74 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
2Q5.F Valuation Measures
| Enterprise Value | 34.9M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.46491227 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.705 |
Trading Information
Renovaro Inc. Stock Price History
| Beta (5Y Monthly) | 1.098591 |
| 52-Week Change | -79.34% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.29 EUR |
| 52 Week Low | 0.53 EUR |
| 50-Day Moving Average | 0.86 EUR |
| 200-Day Moving Average | 1.28 EUR |
2Q5.F Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 58.28M |
| Float | 28.42M |
| Short Ratio | N/A |
| % Held by Insiders | 58.05% |
| % Held by Institutions | 6.55% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -9.93% |
| Return on Equity (ttm) | -93.87% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -20464270 EUR |
| Net Income Avi to Common (ttm) | -106722824 EUR |
| Diluted EPS (ttm) | -1.83 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.95M EUR |
| Total Cash Per Share (mrq) | 0.05 EUR |
| Total Debt (mrq) | 7.54M EUR |
| Total Debt/Equity (mrq) | 11.4 EUR |
| Current Ratio (mrq) | 0.334 |
| Book Value Per Share (mrq) | 1.14 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -12563424 EUR |
| Levered Free Cash Flow (ttm) | -6262458 EUR |
Profile of Renovaro Inc.
| Country | Germany |
| State | CA |
| City | Los Angeles |
| Address | Century City Medical Plaza |
| ZIP | 90067-2012 |
| Phone | 305 918 1980 |
| Website | https://www.enochianbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 22 |
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
Q&A For Renovaro Inc. Stock
What is a current 2Q5.F stock price?
Renovaro Inc. 2Q5.F stock price today per share is 0.81 EUR.
How to purchase Renovaro Inc. stock?
You can buy 2Q5.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Renovaro Inc.?
The stock symbol or ticker of Renovaro Inc. is 2Q5.F.
Which industry does the Renovaro Inc. company belong to?
The Renovaro Inc. industry is Biotechnology.
How many shares does Renovaro Inc. have in circulation?
The max supply of Renovaro Inc. shares is 159.3M.
What is Renovaro Inc. Price to Earnings Ratio (PE Ratio)?
Renovaro Inc. PE Ratio is now.
What was Renovaro Inc. earnings per share over the trailing 12 months (TTM)?
Renovaro Inc. EPS is -0.74 EUR over the trailing 12 months.
Which sector does the Renovaro Inc. company belong to?
The Renovaro Inc. sector is Healthcare.